Case Western Reserve University (CWRU) has granted an exclusive licence to biofirm spinoff ReXceptor to develop an Alzheimer’s Disease (AD) treatment.

Originally approved by the Food and Drug Administration to treat T-cell lumphomas, CWRU research discovered that bexarotene (trademarked as Targretin) also reversed symptoms of AD in mice within 72 hours following a single dose. The findings, published in journal Science, went on to attract widespread media attention.

To date, ReXceptor has secured $1.4m to continue its work. $500k was awarded by the Alzheimer’s Drug Discovery Foundation (ADDF) to the firm, which also collaborated with the BrightFocus Foundation to provide a further $250k. The Ohio-based firm has also received two investments of $450k and $200k from CWRU.

ReXceptor plans to begin early-stage human trials in the coming months that will also involve healthy volunteers in order to demonstrate an effect on humans similar to those observed in animal studies.


Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?